Heart rate variability and quality of life ın patients with breast cancer metastasis

The implementation  of Holter monitoring  (HMECG)  and quality of life questionnaires  in clinical practice allows  for the assessment of the risk of developing dangerous heart rhythm disorders and the most important parameters related to the daily activities of patients with breast cancer. The aim of the study was to evaluate the physical and psychological health, taking into account the variability of heart rate in patients with breast cancer complicated by metastatic lymph node involvement. Material and methods. The study used data from questionnaires  completed by 115 breast cancer patients with metastatic lymph node involvement  who were receiving treatment at the Republican  Oncological  Hospital, divided into two groups: a main group of 45 patients with metastatic breast cancer and lymph node involvement, and a control group of 70 patients without lymph node involvement. The average age of the patients was between 30 and 60 years old. Complaints associated with heart rhythm disorders were considered as criteria for indicating HMECG. Quality of life questionnaires were performed using official versions of EORTC QLQ-C30 and QLQ-C30/BR23 questionnaires. Results. According to the results of statistical analysis, it was found that the effective refractory period of the atria (ERP PR) in the main group during atrial fibrillation (AF) was shorter than in the control group (p = 0.001). It was also found that in addition to shortening the ERP PR, an important factor in diagnosing breast cancer is an increase in the recovery time of the sinus node function and its corrected equivalent (CVVFSU) at relatively low average values of daily, nocturnal, and diurnal heart rate frequencies. Worsening overall condition or general fatigue are some of the most common symptoms encountered in breast cancer patients, which should be considered as important parameters significantly affecting the quality of life of patients burdened with metastatic regional lymph node involvement.

1. Lei S., Zheng R., Zhang S., Wang S., Chen R., Sun K., Zeng H., Zhou J., Wei W. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. (Lond). 2021;41(11):1183-1194. DOI: 10.1002/cac2.12207

2. Kim J.S., Kim J.H., Chang J.H., Kim D.W., Shin K.H. Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis. Front. Oncol. 2022;12:1026043. DOI: 10.3389/fonc.2022.1026043

3. Balmagambetova S., Tlegenova Z., Zholdin B., Kurmanalina G., Talipova I., Koyshybaev A., Nurmanova D., Sultanbekova G., Baspayeva M., Madinova S. et al. Early diagnosis of chemotherapy-linked cardiotoxicity in breast cancer patients using conventional biomarker panel: a prospective study protocol. Diagnostics. 2022;12:2714. DOI: 10.3390/diagnostics12112714

4. Nardin S., Mora E., Varughese F.M., D'Avanzo F., Vachanaram A.R., Rossi V., Saggia C., Rubinelli S., Gennari A. Breast cancer survivorship, quality of life, and late toxicities. Front. Oncol. 2020;10:864. DOI: 10.3389/fonc.2020.00864

5. Doege D., Thong M.S.Y., Koch-Gallenkamp L. et al. Clinical and sociodemographic determinants of disease-specific health-related quality of life in long-term breast cancer survivors. J. Cancer Res. Clin. Oncol. 2022;148;3461-3473. DOI: 10.1007/s00432-022-04204-w

6. Alquraan L., Alzoubi K.H., Rababa'h S., Karasneh R., Al-Azzam S., Al-Azayzih A. Prevalence of depression and the quality-of-life of breast cancer patients in Jordan. J. Multidiscip. Healthc. 2020;13:1455-1462. DOI: 10.2147/JMDH.S277243

7. de Ligt K.M., Heins M., Verloop J., Ezendam N.P.M., Smorenburg C.H., Korevaar J.C., Siesling S. The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors. Breast Cancer Res. Treat. 2019;178(3):703-711. DOI: 10.1007/s10549-019-05433-3

8. Huang, HY., Tsai, WC., Chou, WY. et al. Quality of life of breast and cervical cancer survivors. BMC Women's Health. 2017;17:30. DOI: 10.1186/s12905-017-0387-x

9. Huang W., Xu R., Zhou B., Lin C., Guo Y., Xu H., Guo X. Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. Front. Cardiovasc. Med. 2022;9:912329. DOI: 10.3389/fcvm.2022.912329

10. Rushton M., Kappel C., Lima I., Tuna M., Pritchard K., Hawken S., Dent S. Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada. Front. Cardiovasc. Med. 2022;19;9:850674. DOI: 10.3389/fcvm.2022.850674

11. DeLuna H., Velikov D., Patel H., Feld J., Robin J., Rosenberg C.A., Saha P. Improving cardiac monitoring in patients with early-stage breast cancer receiving cardiotoxic chemotherapy in a multidisciplinary cancer center. J. Clin. Oncol. 2022;40(28):191191. DOI: 10.1200/JCO.2022.40.28_suppl.191

12. Caspi I., Freund O., Biran R., Bornstein G. Holter ECG monitoring for the evaluation of stroke in the internal medicine department. J. Stroke Cerebrovasc. Dis. 2022;31(12):106802. DOI: 10.1016/j.jstrokecerebrovasdis.2022.106802

13. Rushton M., Kappel C., Lima I., Tuna M., Pritchard K., Hawken S., Dent S. Cardiac monitoring and heart failure in advanced breast cancer patients treated with trastuzumab in Ontario, Canada. Front. Cardiovasc. Med. 2022;19;9:850674. DOI: 10.3389/fcvm.2022.850674

14. Balla A., Weaver D.L. Pathologic evaluation of lymph nodes in breast cancer: contemporary approaches and clinical implications. Surg. Pathol. Clin. 2022;15(1):15-27. DOI: 10.1016/j.path.2021.11.002.

15. Hernández-Blanquisett A., Quintero-Carreño V., Álvarez-Londoño A., Martínez-Ávila M.C., Diaz-Cáceres R. Sexual dysfunction as a challenge in treated breast cancer: in-depth analysis and risk assessment to improve individual outcomes. Front. Oncol. 2022;12:955057. DOI: 10.3389/fonc.2022.955057

16. Hoyle E., Kilbreath S., Dylke E. Body image and sexuality concerns in women with breast cancer-related lymphedema: a cross-sectional study. Support Care Cancer. 2022;30(5):3917-3924. DOI: 10.1007/s00520-021-06751-3

17. Poręba M., Gać P., Usnarska-Zubkiewicz L., Pilecki W., Kuliczkowski K., Mazur G., Sobieszczanska M., Poręba R. The analysis of the parameters of 24-hr ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation. Ann. Noninvasive Electrocardiol. 2018;23(4):e12534. DOI: 10.1111/anec.12534

18. Petrovsky A.V., Zhang L., Sobolevsky V.A., Krokhina O.V., Valiev R.K., Nechushkin M.I., Amosova V.A. Quality of life in patients with multicentric breast cancer. Malignant tumors. 2020;10(1):21-28. (In Russian). DOI: 10.18027/2224-5057-2020-10-1-21-28

19. Gonzalez L., Bardach A., Palacios A., Peckaitis C., Ciapponi A., Pichón-Riviere A., Augustovski F., Health-related quality of life in patients with breast cancer in latin america and the caribbean: a systematic review and meta-analysis. The Oncologist. 2021;26(5);794-806. DOI: 10.1002/onco.13709

20. de Ligt K.M., Heins M., Verloop J., Ezendam N.P.M., Smorenburg C.H., Korevaar J.C., Siesling S. The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors. Breast Cancer Res. Treat. 2019;178(3):703-711. DOI: 10.1007/s10549-019-05433-3

21. Ośmiałowska E., Staś J., Chabowski M., Jankowska-Polańska B. Illness Perception and Quality of Life in Patients with Breast Cancer. Cancers (Basel). 2022;14(5):1214. DOI: 10.3390/cancers14051214

22. Gebert P., Dordevic A.D., Roehle R., Hage A.M., Karsten M.M. Data of real-world reference scores for EORTC QLQ-C30 and QLQ-BR23 at baseline in women with early breast cancer and other breast diseases. Data Brief. 2022;43:108347. DOI: 10.1016/j.dib.2022.108347

23. Krohe M., Hao Y., Lamoureux R.E. et al. Patient-reported outcomes in metastatic breast cancer: a review of industry-sponsored clinical trials. Breast Cancer: Basic and Clinical Research. 2016;10:93-102. DOI: 10.4137/bcbcr.s39385

24. Dent S., Moore H., Raval P. et al. How to manage and monitor cardiac dysfunction in patients with metastatic her2-positive breast cancer. J. Am. Coll. Cardiol. CardioOnc. 2022;4(3);404-408. DOI: 10.1016/j.jaccao.2022.06.002

25. Rositch A.F., Unger-Saldana K., DeBoer R.J., Ng'ang'a A., Weiner B.J. The role of dissemination and implementation science in global breast cancer control programs: Frameworks, methods, and examples. Cancer. 2020;126(10);2394-404. DOI: 10.1002/cncr.32877